Efficacy of chronic 5-HT 1A receptor agonism by NLX-112 in a mouse model of Spinocerebellar Ataxia type 3
Authors:
- B Ferreira-LombaBFB Ferreira-Lomba
- S GuerreiroS Guerreiro
- S Duarte-SilvaSDS Duarte-Silva
- D Cunha-GarciaDCD Cunha-Garcia
- S OliveiraSOS Oliveira
- C VieiraCVC Vieira
- J Pereira-SousaJ Pereira-Sousa
- D Vilasboas-CamposDVD Vilasboas-Campos
- A Vidinha-MiraAVA Vidinha-Mira
- D Monteiro-FernandesDMD Monteiro-Fernandes
- Ma VarneyMVMa Varney
- KlevenKLKleven
Preprint
Abstract
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an elongated polyglutamine (polyQ) sequence in the ataxin-3 protein. This expansion triggers neuropathological events, leading to progressive motor disturbances. Currently, no approved therapy exists for this debilitating condition, but compelling evidence suggests that targeting the serotonergic system can significantly attenuate SCA3 disease progression in animal models. Objective: This study aimed to assess the effects of NLX-112, a highly selective serotonin 1A receptor (5-HT 1A R) full agonist, in the CMVMJD135 transgenic mouse model of SCA3. Methods: NLX-112 (0.625 and 5 mg/kg/day) and tandospirone (a 5-HT 1A R partial agonist used as a comparator; 20 and 80 mg/kg/day) were administered chronically in drinking water for 34 weeks, starting prior to symptom onset. To evaluate the effects of the drugs on SCA3 mice, motor-related behavioral tests and neuropathological techniques were employed. Results: Treatment with the higher dose of NLX-112 led to improvements in motor coordination and balance, and slowing of symptom deterioration as the disease progressed. These beneficial effects were not achieved with tandospirone. NLX-112 treatment also elicited neuroprotective effects, reducing dopaminergic (tyrosine hydroxylase-positive) cell loss and astrocyte reactivity in the substantia nigra. Conclusions: NLX-112 treatment, started pre-symptomatically, enhanced motor function, slowed disease progression and elicited neuroprotective effects in SCA3 mice, supporting its further development as a drug candidate for treatment of ataxia and related movement disorders. Graphical Key findings: NLX-112 attenuated motor deficits of SCA3 mice, when administered chronically prior to disease onset. NLX-112 reduced neuropathological biomarkers in SCA3 mice, namely by restoring dopaminergic neuron loss and decreasing astrocyte reactivity. NLX-112 is a potential candidate for addressing ataxia-related deficits in SCA3 patients.Keywords
Funding Information
- Department of Defense (DoD) - U.S. Army Medical Research and Materiel Command (W81XWH-19-1-0638)
- Foundation for Science and Technology (UID/06304/2023)
- Foundation for Science and Technology (LA/P/0050/2020 (DOI 10.54499/LA/P/0050/2020))
- Foundation for Science and Technology (NORTE2030-FEDER01786400)
- Foundation for Science and Technology (PPBI-POCI-01-0145-FEDER-022122)
- Foundation for Science and Technology (2023.15102.PEX)
- Foundation for Science and Technology (CEECIND/00685/2020)
- Ataxia UK
This publication has 69 references indexed in Scilit:
- NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian EfficacyMovement Disorders, 2025
- Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3Movement Disorders, 2018
- Estrogen-regulated progestin receptors are found in the midbrain raphe but not hippocampus of estrogen receptor alpha (ER?) gene-disrupted miceJournal of Comparative Neurology, 2000
- Effects of chronic 17?-estradiol treatment on the serotonin 5-HT1A receptor mRNA and binding levels in the rat brainSynapse, 1999
- Immunocytochemical localization of nuclear estrogen receptors and progestin receptors within the rat dorsal raphe nucleusJournal of Comparative Neurology, 1998
- Buspirone, a 5-Hydroxytryptamine1A Agonist, Is Active in Cerebellar AtaxiaArchives of Neurology, 1997
- Machado–Joseph Disease Gene Product Identified in Lymphocytes and BrainBiochemical and Biophysical Research Communications, 1997
- Immunocytochemical localization of serotonin1A receptors in the rat central nervous systemJournal of Comparative Neurology, 1996
- Use of Buspirone for Treatment of Cerebellar AtaxiaArchives of Neurology, 1995
- Machado‐Joseph disease: An autosomal dominant motor system degenerationMovement Disorders, 1992